Amgen in $1.9bn swoop for Five Prime and its gastric cancer drugAmgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer Share XAmgen in $1.9bn swoop for Five Prime and its gastric cancer drughttps://pharmaphorum.com/news/amgen-in-1-9bn-swoop-for-five-prime-and-its-gastric-cancer-drug/
Five Prime eyes financing after positive results with stomach cancer drugShares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach Share XFive Prime eyes financing after positive results with stomach cancer drughttps://pharmaphorum.com/news/five-prime-eyes-financing-after-positive-results-with-stomach-cancer-drug/
